Entresto Clinical Trials
Here are the 6 most popular medical studies for entresto
Angiotensin Receptor Neprilysin Inhibitor
Entresto + Aprepitant for Heart Failure
Recruiting2 awardsPhase 4
New Haven, Connecticut
This trial is testing whether a drug called Entresto, which is given to people with heart failure, is more effective when taken with or without another drug called Aprepitant.
Angiotensin Receptor Blocker/Neprilysin Inhibitor
LCZ696 for Heart Failure
Recruiting2 awardsPhase 4
Nashville, Tennessee
This trial is testing the hypothesis that the effects of LCZ696 on blood pressure, natriuresis, and diuresis at initiation are due to the inhibition of neprilysin, which degrades endogenous bradykinin. The study will enroll 80 subjects with stable heart failure who will be given LCZ696 50 mg and either the bradykinin B2 receptor antagonist icatibant or placebo vehicle in random order (double-blind).
Popular filter options for entresto trials
Clinical Trials With No Placebo
View 16 medical studies that do not have a placebo group.
Angiotensin Receptor-Neprilysin Inhibitor
Sacubitril-Valsartan +1 More for Heart Failure
Recruiting5 awardsPhase 4
Cleveland, Ohio
This trial is testing a new heart medication in patients with a left ventricular assist device (LVAD). The goal is to see if the new drug is better tolerated and more effective than the current standard of care.
Angiotensin Receptor Neprilysin Inhibitor
Sacubitril/Valsartan for Heart Failure
Recruiting3 awards2 criteria
Toronto, Ontario
The purpose of this study is to compare the changes in B-type Natriuretic Peptide (BNP) and amino-terminal fragment of proBNP (NT-proBNP) in outpatients managed in the heart failure (HF) clinic initiated on the Angiotensin Receptor Neprilysin Inhibitor (Entresto) and directly compare the prognostic values of BNP and NT-proBNP in patients admitted with acute decompensated HF.
Angiotensin Receptor Blocker/Neprilysin Inhibitor
Combination Blood Pressure Therapy for High Blood Pressure
Recruiting3 awardsPhase 4
Nashville, Tennessee
This trial is testing if a two-drug combination can increase blood flow more than one of the drugs can on its own, and if a third drug can interact with the first two to also increase blood flow.
Angiotensin Receptor Neprilysin Inhibitor
Sacubitril/valsartan +5 More for Congestive Heart Failure
Recruiting3 awardsPhase 4
Huntsville, Alabama
This trial is being done to see which treatment options work best for people with congestive heart failure. They will be looking at different treatments like observing the patients, giving them diuretic medicine, or
View More Entresto Trials
See another 3 medical studies focused on entresto.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.